Copenhagen-based Dawn Health has secured €11.5 million in fresh funding from existing investors Chr. Augustinus Fabrikker, the Export and Investment Fund of Denmark (EIFO), and Trifork. The investment will support the company's strategy to scale its regulatory-grade digital health platform and expand its product suite for pharmaceutical companies globally.
The funding comes at a pivotal time for Dawn Health, which has been developing its specialized platform since 2021. The company has already established partnerships with five global pharmaceutical leaders, including Merck and Novartis, and plans to accelerate its Software-as-a-Service (SaaS) delivery model with this new capital injection.
"Our ambition is to be the global leader in digital health, powering pharma's next-generation products – and ultimately improving the lives of patients worldwide," said Alexander Mandix Hansen, CEO of Dawn Health. "This funding allows us to bring our proven platform to more markets and deepen our impact."
Platform Capabilities and Clinical Applications
The Dawn Platform leverages advanced capabilities in artificial intelligence, data analytics, and connected health technologies to support patients across multiple therapeutic areas. Currently, the platform is being utilized in oncology, multiple sclerosis, and rare pediatric conditions such as growth disorders.
For patients, the platform offers tools to manage treatment regimens, report symptoms, and maintain close communication with healthcare providers. These features create a comprehensive digital ecosystem that enhances patient care while simultaneously generating valuable real-world evidence for pharmaceutical partners.
The platform's AI-driven capabilities enable personalized patient experiences while facilitating data collection and analytics that benefit both patients and pharmaceutical companies. This dual-value proposition positions Dawn Health's technology as the foundation for therapy companions, disease management programs, and real-world evidence solutions.
Growth Trajectory and Market Position
Since receiving a major investment in December 2021, Dawn Health has significantly expanded its market presence and revenue streams. The company now employs more than 100 staff and has developed a robust regulatory infrastructure to support its pharmaceutical partnerships.
"Since the major investment in December 2021, Dawn Health has grown its revenue significantly and expanded its footprint in global pharma. With more than 100 employees, unique solutions, and a strong regulatory infrastructure, we are prepared to further accelerate our growth," noted Chairman Lars Marcher.
The latest funding round will enable Dawn Health to strengthen its position as a trusted partner to pharmaceutical companies by delivering scalable, regulatory-grade digital health products that evolve with the needs of modern medicine.
Future Directions
As the healthcare industry continues to embrace digital transformation, Dawn Health is strategically positioned to lead innovation in pharmaceutical digital health solutions. The company specializes in developing Software as a Medical Device (SaMD), Digital Therapeutics (DTx), and connected health solutions that accelerate the launch of digital interventions to market.
Through its human-centric approach, Dawn Health aims to transform patient care for those with chronic conditions while providing pharmaceutical partners with valuable insights and enhanced treatment options. The additional funding will support further product development and international expansion, reinforcing the company's mission to improve patient outcomes through digital innovation.
